Front Immunol. 2015 Sep 30;6:503. doi: 10.3389/fimmu.2015.00503. eCollection 2015.

Mucosal-Associated Invariant T Cells in Multiple Sclerosis: The Jury is Still Out.

Frontiers in immunology

Emmanuel Treiner, Roland S Liblau

PMID: 26483793 PMCID: PMC4588106 DOI: 10.3389/fimmu.2015.00503

Abstract

The immune system is strongly implicated in the pathophysiology of multiple sclerosis (MS), as demonstrated by the efficacy of therapies targeting various components of adaptive immunity. However, the disease still progresses despite these treatments in many patients, while others experience life-threatening adverse effects, urging for the discovery of new immune-targeting medications. Among the immune cell types participating to MS pathogenesis, decades of work have highlighted the prominent role of CD4 T cells. More recent data demonstrate the involvement of CD8 T cells as well. The existence of both pathogenic and protective CD8 T cells subsets has been suggested, adding an additional layer of complexity to the picture. Mucosal-associated invariant T (MAIT) cells are innate-like lymphocytes that make up to 25% of CD8 T cells in healthy subjects. They are specific for conserved microbial ligands and may constitute an important barrier against invasive bacterial and fungal infection. An increasing number of reports also suggest their possible involvement in chronic inflammatory diseases, including MS. MAIT cells could participate through their ability to produce IFNγ and/or IL-17, two major cytokines in the pathogenesis of several chronic inflammatory/autoimmune diseases. However, the mechanisms by which MAIT cells could be activated in these sterile conditions are not known. Furthermore, contradictory observations have been made, reporting either a protective or a pro-inflammatory behavior of MAIT cells in MS or its murine model, experimental autoimmune encephalomyelitis. In this review article, we will describe the current knowledge on MAIT cell biology in health and disease, and discuss the possible mechanisms behind their role in MS. The specific features of this new non-conventional T cell subset make it an interesting candidate as a biomarker or as the target of immune-mediated intervention.

Keywords: IFN gamma; MHC-related 1; adaptive immunity; innate-like T cells; multiple sclerosis

References

1. J Immunol. 2014 Oct 15;193(8):3891-901 - PubMed
2. Int Immunol. 2004 Feb;16(2):223-30 - PubMed
3. J Korean Med Sci. 2015 May;30(5):606-11 - PubMed
4. Trends Immunol. 2011 May;32(5):212-8 - PubMed
5. Immunogenetics. 2013 Feb;65(2):115-24 - PubMed
6. Blood. 2012 Jan 12;119(2):422-33 - PubMed
7. J Exp Med. 2014 Jul 28;211(8):1601-10 - PubMed
8. Nature. 2011 Aug 10;476(7359):214-9 - PubMed
9. J Exp Med. 2013 Oct 21;210(11):2305-20 - PubMed
10. Nat Commun. 2014 May 15;5:3866 - PubMed
11. Sci Signal. 2012 May 22;5(225):ra38 - PubMed
12. Nature. 2012 Nov 29;491(7426):717-23 - PubMed
13. Semin Immunol. 2013 Dec 15;25(6):439-48 - PubMed
14. Immunol Rev. 2015 Mar;264(1):154-66 - PubMed
15. AIDS. 2014 Jul 17;28(11):1690-2 - PubMed
16. Brain. 2015 Mar;138(Pt 3):644-52 - PubMed
17. J Allergy Clin Immunol. 2015 Aug;136(2):323-33 - PubMed
18. FEBS Lett. 2014 Nov 17;588(22):4207-13 - PubMed
19. Immunology. 2015 Jul;145(3):443-53 - PubMed
20. Mucosal Immunol. 2015 Mar;8(2):429-40 - PubMed
21. PLoS Biol. 2010 Jun 29;8(6):e1000407 - PubMed
22. Blood. 2011 Sep 8;118(10):2752-62 - PubMed
23. PLoS One. 2014 Sep 03;9(9):e106335 - PubMed
24. Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):E3119-28 - PubMed
25. Proc Natl Acad Sci U S A. 2009 May 19;106(20):8290-5 - PubMed
26. J Immunol. 2013 Apr 1;190(7):3142-52 - PubMed
27. PLoS Negl Trop Dis. 2014 Aug 21;8(8):e3076 - PubMed
28. Infect Immun. 2012 Sep;80(9):3256-67 - PubMed
29. Int Immunol. 2011 Sep;23(9):529-35 - PubMed
30. JAMA Neurol. 2013 Oct;70(10):1315-24 - PubMed
31. Clin Exp Immunol. 2014 May;176(2):266-74 - PubMed
32. Neurol Neuroimmunol Neuroinflamm. 2015 May 07;2(4):e107 - PubMed
33. Curr Opin Immunol. 2014 Feb;26:7-13 - PubMed
34. PLoS One. 2015 Apr 08;10(4):e0121124 - PubMed
35. J Immunol. 2013 Dec 15;191(12 ):6002-9 - PubMed
36. PLoS Biol. 2009 Mar 10;7(3):e54 - PubMed
37. PLoS One. 2013 Dec 31;8(12):e83474 - PubMed
38. Ann Neurol. 2013 Sep;74(3):317-27 - PubMed
39. Nature. 2014 May 15;509(7500):361-5 - PubMed
40. J Clin Invest. 2015 Apr;125(4):1752-62 - PubMed
41. J Autoimmun. 2014 Nov;54:33-50 - PubMed
42. Blood. 2013 Feb 7;121(6):951-61 - PubMed
43. J Clin Invest. 2012 Apr;122(4):1180-8 - PubMed
44. PLoS One. 2014 Nov 04;9(11):e111323 - PubMed
45. Intensive Care Med. 2014 Feb;40(2):192-201 - PubMed
46. Nat Immunol. 2010 Aug;11(8):701-8 - PubMed
47. Brain. 2013 Sep;136(Pt 9):2888-903 - PubMed
48. Arthritis Rheum. 2012 Jan;64(1):153-61 - PubMed
49. Nat Genet. 2013 Nov;45(11):1353-60 - PubMed
50. J Exp Med. 2015 Jun 29;212(7):1095-108 - PubMed
51. J Invest Dermatol. 2014 Dec;134(12):2898-907 - PubMed
52. FEBS Lett. 2011 Dec 1;585(23):3758-63 - PubMed
53. Nat Immunol. 2006 Sep;7(9):987-94 - PubMed
54. Brain. 2011 Feb;134(Pt 2):542-54 - PubMed
55. Nat Commun. 2014;5:3143 - PubMed
56. Blood. 2011 Jan 27;117(4):1250-9 - PubMed
57. Eur J Immunol. 2014 Oct;44(10):3119-28 - PubMed
58. Blood. 2013 Feb 14;121(7):1124-35 - PubMed
59. Sci Transl Med. 2015 Jun 10;7(291):291ra93 - PubMed
60. Nat Med. 2010 Apr;16(4):406-12 - PubMed
61. PLoS One. 2015 Apr 20;10(4):e0124659 - PubMed
62. PLoS Pathog. 2014 Jun 26;10(6):e1004210 - PubMed
63. J Immunol. 2015 May 15;194(10 ):4641-9 - PubMed
64. PLoS One. 2013 Oct 04;8(10):e76008 - PubMed
65. J Autoimmun. 2013 Sep;45:31-9 - PubMed
66. Vet Res. 2010 Sep-Oct;41(5):62 - PubMed
67. Immunol Cell Biol. 2015 Feb;93(2):177-88 - PubMed
68. J Exp Med. 1999 Jun 21;189(12):1907-21 - PubMed
69. Front Immunol. 2014 Jan 07;4:511 - PubMed
70. Nature. 2003 Mar 13;422(6928):164-9 - PubMed
71. Eur J Immunol. 2014 Jan;44(1):195-203 - PubMed
72. J Immunol. 2015 Jun 15;194(12):5775-80 - PubMed
73. Int Immunol. 2008 Dec;20(12):1517-25 - PubMed
74. PLoS Pathog. 2013;9(10 ):e1003681 - PubMed

Publication Types

• Journal Article
• Review